These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 2526385)

  • 1. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 5. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
    Bourgain RH; Andries R; Decuyper K; De Clerck F
    J Lipid Mediat; 1991; 3(1):3-11. PubMed ID: 1837488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review.
    Fiddler GI; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
    Vandeplassche G; Hermans C; Van Dael L; Wouters L; De Clerck F
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):56-69. PubMed ID: 7678680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.
    Hoet B; Falcon C; De Reys S; Arnout J; Deckmyn H; Vermylen J
    Blood; 1990 Feb; 75(3):646-53. PubMed ID: 2153424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.
    Aoki N; Johnson G; Siegfried MR; Lefer AM
    Eicosanoids; 1989; 2(3):169-74. PubMed ID: 2534278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.